Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
Ilse TackAsnake DumichoLiesbet OhlerAltynay ShigayevaAbera Balcha BultiKenneth WhiteMduduzi MbathaJennifer FurinPetros IsaakidisPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. AEs are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to train staff in the monitoring, management, and reporting of AEs.
Keyphrases
- human immunodeficiency virus
- south africa
- antiretroviral therapy
- hiv positive
- hepatitis c virus
- hiv infected
- hiv aids
- mycobacterium tuberculosis
- randomized controlled trial
- multidrug resistant
- drug resistant
- type diabetes
- combination therapy
- high resolution
- quality improvement
- metabolic syndrome
- skeletal muscle
- adverse drug
- adipose tissue
- mass spectrometry
- weight loss
- smoking cessation
- glycemic control